pan-RAF inhibitor

DRUG CLASS:

pan-RAF inhibitor

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
BRAF fusion	Glioma	BRAF fusion	Glioma	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1
BRAF V600	Glioma	BRAF V600	Glioma	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1
BRAF rearrangement	Glioma	BRAF rearrangement	Glioma	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
BRAF fusion	Melanoma	BRAF fusion	Melanoma	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	sorafenib + everolimus Sensitive: A2 - Guideline sorafenib + everolimus Sensitive : A2	sorafenib + everolimus Sensitive: A2 - Guideline sorafenib + everolimus Sensitive : A2
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	sorafenib Resistant: A2 - Guideline sorafenib Resistant : A2	sorafenib Resistant: A2 - Guideline sorafenib Resistant : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
RAF1 amplification	Melanoma	RAF1 amplification	Melanoma	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B
KRAS amplification	Melanoma	KRAS amplification	Melanoma	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B
CCND1 amplification	Melanoma	CCND1 amplification	Melanoma	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B
HGF elevation + VEGFA elevation	Hepatocellular Cancer	HGF elevation + VEGFA elevation	Hepatocellular Cancer	erlotinib + sorafenib Resistant: B - Late Trials erlotinib + sorafenib Resistant : B	erlotinib + sorafenib Resistant: B - Late Trials erlotinib + sorafenib Resistant : B
NRAS mutation	Melanoma	NRAS mutation	Melanoma	KIN-2787 Sensitive: B - Late Trials KIN-2787 Sensitive : B	KIN-2787 Sensitive: B - Late Trials KIN-2787 Sensitive : B
BRAF mutation	Melanoma	BRAF mutation	Melanoma	KIN-2787 Sensitive: B - Late Trials KIN-2787 Sensitive : B	KIN-2787 Sensitive: B - Late Trials KIN-2787 Sensitive : B
NRAS mutation	Melanoma	NRAS mutation	Melanoma	trametinib + ERAS-254 Sensitive: B - Late Trials trametinib + ERAS-254 Sensitive : B	trametinib + ERAS-254 Sensitive: B - Late Trials trametinib + ERAS-254 Sensitive : B
No biomarker	Glioma	No biomarker	Glioma	tovorafenib Sensitive: B - Late Trials tovorafenib Sensitive : B	tovorafenib Sensitive: B - Late Trials tovorafenib Sensitive : B
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	ERAS-254 Sensitive: C2 – Inclusion Criteria ERAS-254 Sensitive : C2	ERAS-254 Sensitive: C2 – Inclusion Criteria ERAS-254 Sensitive : C2
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	sorafenib + LY2157299 Sensitive: C2 – Inclusion Criteria sorafenib + LY2157299 Sensitive : C2	sorafenib + LY2157299 Sensitive: C2 – Inclusion Criteria sorafenib + LY2157299 Sensitive : C2

pan-RAF inhibitor

pan-RAF inhibitor

Associations(282)

Associations
(282)